Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.9199
-0.0439 (-4.55%)
At close: Aug 1, 2025, 4:00 PM
0.9206
+0.0007 (0.08%)
After-hours: Aug 1, 2025, 5:09 PM EDT

Company Description

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.

Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer’s disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig’s disease.

The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.

Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Klotho Neurosciences, Inc.
Klotho Neurosciences logo
CountryUnited States
Founded2019
IndustryBiotechnology
SectorHealthcare
Employees3
CEOJoseph Sinkule

Contact Details

Address:
13576 Walnut Street, Suite A
Omaha, Nebraska 68144
United States
Phone833 931 6330
Websiteklothoneuro.com

Stock Details

Ticker SymbolKLTO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001907223
ISIN NumberUS49876K1034
Employer ID86-2727441
SIC Code2836

Key Executives

NamePosition
Dr. Joseph Sinkule Pharm.D.Founder, Chief Executive Officer, Chairman of the Board and Secretary
Jeffrey LeBlancChief Financial Officer
Dr. Shalom Z. Hirschman M.D.Medical Advisor and Director
Peter J. MoriartyChief Business Officer
Dr. Miguel Chillon RodriguezChief Scientific Advisor and Consultant
Dr. Bradford A. Navia M.D., Ph.D.Chief Medical Advisor

Latest SEC Filings

DateTypeTitle
Jul 28, 2025424B5Filing
Jul 28, 2025424B3Prospectus
Jul 28, 2025424B3Prospectus
Jul 25, 2025EFFECTNotice of Effectiveness
Jul 23, 20258-K/A[Amend] Current report
Jul 22, 20258-KCurrent Report
Jul 18, 20258-KCurrent Report
Jul 10, 20258-KCurrent Report
Jul 7, 2025S-3Registration statement under Securities Act of 1933
Jul 2, 2025SCHEDULE 13G/AFiling